JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

[Diagnosis of Hereditary Tumors Using Multi Gene Panel Testing(MGPT)-Current Status and Issues in Japan or Worldwide]

  • 0Dept. of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.
Gan to Kagaku Ryoho. Cancer & Chemotherapy +

|

August 27, 2024

|

August 27, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Genetic testing for hereditary tumors enables early cancer detection and personalized prevention strategies. Multi gene panel testing (MGPT) is becoming a global standard for diagnosing hereditary cancers.

Area Of Science

  • Oncology
  • Genetics
  • Medical Diagnostics

Context

  • Individuals with pathogenic variants for hereditary tumors face elevated risks of developing multiple cancers.
  • Genetic testing offers a crucial opportunity for proactive cancer surveillance and early detection.
  • Personalized preventive strategies, including risk-reductive surgery, can be developed based on genetic findings.

Purpose

  • To highlight the role of genetic testing in managing hereditary cancer risks.
  • To introduce Multi gene panel testing (MGPT) as a diagnostic tool for hereditary tumors.
  • To discuss the current status and future potential of MGPT in Japan.

Summary

  • Pathogenic variant carriers of hereditary tumors are at high risk for developing cancers in multiple organs.
  • Multi gene panel testing (MGPT), analyzing dozens to over 100 genes simultaneously, has been widely adopted globally for hereditary tumor diagnosis since approximately 2014.
  • While MGPT is not yet approved under Japan's Pharmaceutical and Medical Devices Act, it is anticipated to become the mainstream diagnostic approach for hereditary tumors in the near future.

Impact

  • Empowers early cancer detection and prevention in hereditary cancer syndromes.
  • Facilitates the development of individualized cancer prevention strategies, including prophylactic surgeries.
  • Positions MGPT as a transformative technology for hereditary cancer diagnosis, with significant future implications for patient care and management.